Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975–2013

International Journal of Cancer

Volumn 141, Issue 11, 2017, Pages 2228-2242

  Kvale R ^a,b,c   Myklebust, T A ^a   Engholm, G ^d   Heinavaara S ^e   Wist, E ^f   Moller B ^a  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e FINNISH CANCER REGISTRY   (Finland)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

breast cancer; incidence; mortality; prostate cancer; screening

Indexed keywords

AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; FEMALE; FINLAND; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NORWAY; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; SWEDEN; TREND STUDY; ADULT; AGE DISTRIBUTION; BREAST NEOPLASMS; COMPARATIVE STUDY; INCIDENCE; MIDDLE AGED; PROSTATIC NEOPLASMS; REGISTER; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DENMARK; FEMALE; FINLAND; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NORWAY; PROSTATIC NEOPLASMS; REGISTRIES; SWEDEN;

EID: 85028303916     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30924     Document Type: Article

References (50)

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079–92.
2. DeSantis CE, Bray F, Ferlay J, et al. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 2015;24:1495–506.
3. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027–35.
4. Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013;108:2205–40.
5. Etzioni R, Gulati R, Mallinger L, et al. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med 2013;158:831–8.
6. Kvåle R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881–7.
7. Fall K, Stromberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008;42:352–7.
8. Grulich AE, Swerdlow AJ, dos Santos Silva I, et al. Is the apparent rise in cancer mortality in the elderly real? Analysis of changes in certification and coding of cause of death in England and Wales, 1970–1990. Int J Cancer 1995;63:164–8.
9. Engholm GFJ, Christensen N, Kejs AMT, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, version 7.2 (16.12.2015). Association of the Nordic Cancer Registries. Dan Cancer Soc Available at: http://www.ancr.nu (last accessed 12/01/2017).
10. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218–31.
11. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011;39:42–5.
12. Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33.
13. Leinonen MMJ, Heikkinen S, Pitkäniemi J, et al. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid tumours. Eur J Cancer 2017;77:31–9.
14. Joinpoint Regression Program, Version 4.2.0.1; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute. Available at: https://surveillance.cancer.gov/joinpoint/
15. DeMichele A, Putt M, Zhang Y, et al. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer 2003;97:2150–9.
16. Poulsen MH, Dysager L, Gerke O, et al. Trends in prostate cancer in elderly in Denmark, 1980–2012. Acta Oncol 2016;55(Suppl 1):74–8
17. Etzioni R, Mucci L, Chen S, et al. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res 2012;18:6742–7.
18. Kvåle R, Møller B, Angelsen A, et al. Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007. Cancer Epidemiol 2010;34:359–67.
19. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–42.
20. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066–73.
21. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–5.
22. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–60.
23. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33.
24. Helgesen F, Holmberg L, Johansson JE, et al. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst 1996;88:1216–21.
25. World Cancer Research Fund International/American Institute for Cancer Research Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer. 2014. Available at: www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf (last accessed 20/06/2017).
26. Autier P, Boniol M, Gavin A, et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011;343:d4411.
27. Sarkeala T, Anttila A, Forsman H, et al. Process indicators from ten centres in the Finnish breast cancer screening programme from 1991 to 2000. Eur J Cancer 2004;40:2116–25.
28. Sarkeala T, Heinävaara S, Anttila A. Breast cancer mortality with varying invitational policies in organised mammography. Br J Cancer 2008;98:641–5.
29. Hofvind S, Geller B, Vacek PM, et al. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol 2007;22:447–55.
30. Olsson S, Andersson I, Karlberg I, et al. Implementation of service screening with mammography in Sweden: from pilot study to nationwide programme. J Med Screen 2000;7:14–8.
31. Christiansen P, Vejborg I, Kroman N, et al. Position paper: breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol 2014;53:433–44.
32. Olsen AH, Jensen A, Njor SH, et al. Breast cancer incidence after the start of mammography screening in Denmark. Br J Cancer 2003;88:362–5.
33. Jensen A, Olsen AH, von Euler-Chelpin M, et al. Do nonattenders in mammography screening programmes seek mammography elsewhere? Int J Cancer 2005;113:464–70.
34. Baum M, Brinkley DM, Dossett JA, et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983;2:450.
35. Early Breast Cancer Trialists' Collaborative G. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681–92.
36. Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432–44.
37. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–2.
38. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
39. EBCTCG, McGale P, Taylor C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127–35.
40. The Danish National Board of Health. National Kræftplan. Status og forslag til initiativer i relation til kræftbehandlingen. Copenhagen: The Danish National Board of Health, 2000. 1–161.
41. Collaborators GBDRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1659–724. Estimates available at: http://ihmeuw.org/44qg (last accessed 27/06/2017).
42. Jensen JD, Cold S, Nielsen MH, et al. Trends in breast cancer in the elderly in Denmark, 1980–2012. Acta Oncol 2016;55(Suppl 1):59–64.
43. Danish Breast Cancer Cooperative Group. Available at: http://dbcg.dk/ (last accessed 20/03/2017).
44. Bihrmann K, Jensen A, Olsen AH, et al. Performance of systematic and non-systematic (‘opportunistic') screening mammography: a comparative study from Denmark. J Med Screen 2008;15:23–6.
45. Arnsrud Godtman R, Holmberg E, Lilja H, et al. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial. Eur Urol 2015;68:354–60.
46. Sørum R, Hofvind S, Skaane P, et al. Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme. Breast 2010;19:499–505.
47. Sundhedsdatastyrelsen. Available at: http://www.esundhed.dk/sundhedsregistre/CAR/CAR02/Sider/Tabel.aspx (last accessed 20/03/ 2017).
48. Ozanne EM, Shieh Y, Barnes J, et al. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 2011;129:165–73.
49. Hemminki E, Kyyrönen P, Pukkala E. Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995–2005. Maturitas 2008;61:299–304.
50. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer – part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999;91:1025–32.